| Abstract [eng] |
This study analyses influence of the clinical and molecular prognostic factors on the survival in patients with invasive urothelial bladder cancer that were treated by various treatment methods. Prospective analysis was done to investigate the value of the clinical and molecular prognostic factors on survival in patients treated by chemoradiotherapy with gemcitabine. Retrospective analysis investigated the value of clinical prognostic factors on survival in patients treated by radical cystectomy and radiotherapy. In this study have been investigated impact of age, sex, radicality of transurthral resection of bladder tumor, T stage, hydronephrosis, concomitant diseases, total doses of chemoradiation on survival. Impact of molecular markers on survival in patients treated by chemoradiotherapy was assessed. Patients with invasive urothelial bladder cancer were given the combined treatment modality of gemcitabine (dose 300 mg/m2 weekly) with radiotherapy as bladder sparing treatment. |
